Predicting ICU Mortality in ARDS Patients

NCT ID: NCT05611177

Last Updated: 2023-08-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1303 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-14

Study Completion Date

2023-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are planning to perform a secondary analysis of an academic dataset of 1,303 patients with moderate-to-severe acute respiratory distress syndrome (ARDS) included in several published cohorts (NCT00736892, NCT02288949, NCT02836444, NCT03145974), aimed to characterize the best early model to predict duration of mechanical ventilation and mortality in the intensive care unit (ICU) after ARDS diagnosis using machine learning approaches.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The acute respiratory distress syndrome (ARDS) is a severe form of acute hypoxemic respiratory failure in Critical Care Units worldwide. Most ARDS patients requiere mechanical ventilation (MV). Few studies have investigated the prediction of MV duration and mortality of ARDS.

For model description, the investigators will extract data from the first two ICU days after diagnosis of moderate-to-severe ARDS from patients included in the de-identified database, which includes 1,303 mechanically ventilated patients enrolled in several observational cohorts in Spain, coordinated by the principal investigator (JV), and funded by the Instituto de Salud Carlos III (ISCIII). The investigators will follow the TRIPOD guidelines and machine learning tecniques will be implemented (Random Forest, XGBoost, Logistic regression analysis, and/or neural networks) for development of the prediction model, and the accuracy will be compared to those of existing scoring systems for assessing ICU severity (APACHE II, SOFA) and the PaO2/FiO2 ratio. For external validation, the investigators will use 303 patients enrolled in a contemporary observational study (NCT03145974). The investigators will evaluate the accuracy of prediction models by calculating the respective confusion matrices and several statistics such as sensitivity, specificity, positive predictive value, and negative predictive value for mortality and duration of MV. Investigators will select the best probabilistic model with a minimum number of clinical variables.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Respiratory Distress Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Derivation cohort

It will contain 700 patients (70% of 1000 ARDS patients)

machine learning analysis

Intervention Type OTHER

We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.

Validation cohort

It will contain 300 patients (30% of 1000 ARDS patients)

machine learning analysis

Intervention Type OTHER

We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.

Confirmatory cohort

It will contain 303 patients (for external validation)

machine learning analysis

Intervention Type OTHER

We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

machine learning analysis

We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Logistic regression cross-validation are aunder the ROC curves

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Berlin criteria for moderate to severe ARDS

Exclusion Criteria

* Postoperative patients ventilated \<24h; brain death patients.
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Unity Health Toronto

OTHER

Sponsor Role collaborator

Dr. Negrin University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jesus Villar

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jesús Villar, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario D. Negrin

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario Dr. Negrin

Las Palmas de Gran Canaria, Las Palmas, Spain

Site Status

Department of Anesthesia, Hospital Clinic

Barcelona, , Spain

Site Status

Hospital Universitario La Paz (ICU)

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Villar J, Ambros A, Mosteiro F, Martinez D, Fernandez L, Ferrando C, Carriedo D, Soler JA, Parrilla D, Hernandez M, Andaluz-Ojeda D, Anon JM, Vidal A, Gonzalez-Higueras E, Martin-Rodriguez C, Diaz-Lamas AM, Blanco J, Belda J, Diaz-Dominguez FJ, Rico-Feijoo J, Martin-Delgado C, Romera MA, Gonzalez-Martin JM, Fernandez RL, Kacmarek RM; Spanish Initiative for Epidemiology, Stratification and Therapies of ARDS (SIESTA) Network. A Prognostic Enrichment Strategy for Selection of Patients With Acute Respiratory Distress Syndrome in Clinical Trials. Crit Care Med. 2019 Mar;47(3):377-385. doi: 10.1097/CCM.0000000000003624.

Reference Type BACKGROUND
PMID: 30624279 (View on PubMed)

Huang B, Liang D, Zou R, Yu X, Dan G, Huang H, Liu H, Liu Y. Mortality prediction for patients with acute respiratory distress syndrome based on machine learning: a population-based study. Ann Transl Med. 2021 May;9(9):794. doi: 10.21037/atm-20-6624.

Reference Type BACKGROUND
PMID: 34268407 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

7/2021

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Intensive Care Unit Risk Score
NCT04661735 RECRUITING